Moderna Inc
MRNA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$456.00 | Cljxt | Cpqcypchj |
Moderna's mRNA Technology Could Build a Moat in Vaccines and Cancer and Rare-Disease Treatments
Business Strategy and Outlook
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape for innovative vaccines.